Evaluating ADHD medication trial representativeness: a Swedish population-based study comparing hypothetically trial-eligible and trial-ineligible individuals
Authors:
- Miguel Garcia-ArgibayMGMiguel Garcia-Argibay
- Samuele CorteseSCSamuele Cortese
Top Cited Papers
Open Access
- 6 January 2025
- journal article
- research article
- Published by Elsevier in The Lancet Psychiatry
- Vol. 12 (2) , 131-139
Abstract
No abstract availableKeywords
Funding Information
- Horizon Europe
- National Institute for Health and Care Research
- European Research Executive Agency
This publication has 22 references indexed in Scilit:
- Methylphenidate and Short-Term Cardiovascular RiskJAMA Network Open, 2024
- Attention-Deficit/Hyperactivity Disorder and Major Depressive Disorder: Evidence From Multiple Genetically Informed DesignsBiological Psychiatry, 2023
- Attention‐deficit/hyperactivity disorder is associated with increased risk of cardiovascular diseases: A systematic review and meta‐analysisJCPP Advances, 2023
- Attention-deficit/hyperactivity disorder medication consumption in 64 countries and regions from 2015 to 2019: a longitudinal studyeClinicalMedicine, 2023
- The association between type 2 diabetes and attention- deficit/hyperactivity disorder: A systematic review, meta-analysis, and population-based sibling studyNeuroscience & Biobehavioral Reviews, 2023
- Cardiovascular risk factors in attention‐deficit/hyperactivity disorder: A family design study of Swedish conscriptsInternational Journal of Methods in Psychiatric Research, 2022
- Representation and Outcomes of Individuals With Schizophrenia Seen in Everyday Practice Who Are Ineligible for Randomized Clinical TrialsJAMA Psychiatry, 2022
- Assessment of Stimulant Use and Cardiovascular Event Risks Among Older AdultsJAMA Network Open, 2021
- The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorderNeuroscience & Biobehavioral Reviews, 2021
- Risks and Benefits of Attention-Deficit/Hyperactivity Disorder Medication on Behavioral and Neuropsychiatric Outcomes: A Qualitative Review of Pharmacoepidemiology Studies Using Linked Prescription DatabasesBiological Psychiatry, 2019